Ulrich Wendt is our Chief Business Officer leading the expansion of partnerships with biopharma for the development of novel antibody therapeutics.

Prior to joining Alchemab, Ulrich served as Global Head of Business Development Immunology at Sanofi. Prior to this he drove global Business Development for the diabetes and primary care business units and oversaw global search & evaluation and alliance management teams in cardiometabolic disease. With academic roots in biostructure and biophysics, Ulrich earned his PhD from Freiburg University, completed postdoctoral training at UC Berkeley and Genentech, and earned an MBA from IMD, Lausanne.